Insider Transactions in Q1 2025 at Artivion, Inc. (AORT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
18,020
-8.37%
|
$414,460
$23.61 P/Share
|
|
Mar 11
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,092
+8.15%
|
$400,932
$21.55 P/Share
|
|
Mar 11
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,100
-6.74%
|
$347,300
$23.61 P/Share
|
|
Mar 11
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,910
+6.64%
|
$334,110
$21.55 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
88,439
-4.79%
|
$2,122,536
$24.78 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,615
+7.47%
|
$1,587,915
$21.55 P/Share
|
|
Mar 06
2025
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,701
+11.64%
|
-
|
|
Mar 06
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,048
-0.71%
|
$25,152
$24.8 P/Share
|
|
Mar 06
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,261
+6.5%
|
-
|
|
Mar 06
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,618
-1.24%
|
$62,832
$24.8 P/Share
|
|
Mar 06
2025
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,654
+10.86%
|
-
|
|
Mar 06
2025
|
Lance A Berry Executive VP, CFO |
SELL
Open market or private sale
|
Direct |
4,909
-3.1%
|
$117,816
$24.8 P/Share
|
|
Mar 06
2025
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
48,100
+23.3%
|
-
|
|
Mar 06
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,124
-1.07%
|
$50,976
$24.8 P/Share
|
|
Mar 06
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,493
+11.39%
|
-
|
|
Mar 06
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
1,603
-1.36%
|
$38,472
$24.8 P/Share
|
|
Mar 06
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
19,240
+14.07%
|
-
|
|
Mar 05
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
472
-0.27%
|
$11,800
$25.29 P/Share
|
|
Mar 05
2025
|
Anthony B. Semedo Director |
BUY
Open market or private purchase
|
Indirect |
600
+50.0%
|
$15,000
$25.25 P/Share
|
|
Mar 05
2025
|
Anthony B. Semedo Director |
BUY
Open market or private purchase
|
Direct |
1,500
+4.04%
|
$37,500
$25.33 P/Share
|
|
Feb 28
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,297
+4.38%
|
-
|
|
Feb 28
2025
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,524
+11.44%
|
-
|
|
Feb 28
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
18,398
+15.77%
|
-
|
|
Feb 28
2025
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,301
+11.61%
|
-
|
|
Feb 28
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,416
+11.91%
|
-
|
|
Feb 28
2025
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
34,435
+23.8%
|
-
|
|
Feb 24
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,323
-0.62%
|
$89,721
$27.31 P/Share
|
|
Feb 24
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
42,156
-1.53%
|
$1,138,212
$27.31 P/Share
|
|
Feb 24
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,335
-0.87%
|
$144,045
$27.31 P/Share
|
|
Feb 24
2025
|
Lance A Berry Executive VP, CFO |
SELL
Open market or private sale
|
Direct |
3,259
-4.12%
|
$87,993
$27.31 P/Share
|
|
Feb 24
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,457
-0.98%
|
$174,339
$27.31 P/Share
|
|
Feb 24
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
4,687
-1.41%
|
$126,549
$27.31 P/Share
|